32 related articles for article (PubMed ID: 19825952)
1. Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion.
Nevo J; Mai A; Tuomi S; Pellinen T; Pentikäinen OT; Heikkilä P; Lundin J; Joensuu H; Bono P; Ivaska J
Oncogene; 2010 Dec; 29(49):6452-63. PubMed ID: 20802519
[TBL] [Abstract][Full Text] [Related]
2. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells.
Cai WQ; Zeng LS; Wang LF; Wang YY; Cheng JT; Zhang Y; Han ZW; Zhou Y; Huang SL; Wang XW; Peng XC; Xiang Y; Ma Z; Cui SZ; Xin HW
Front Oncol; 2020; 10():1249. PubMed ID: 32793499
[TBL] [Abstract][Full Text] [Related]
3. Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas.
Meseure D; Drak Alsibai K; Vacher S; Hatem R; Nicolas A; Callens C; Lerebours F; Bieche I
Anal Cell Pathol (Amst); 2020; 2020():9268236. PubMed ID: 32377505
[TBL] [Abstract][Full Text] [Related]
4. Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization.
Le Joncour V; Filppu P; Hyvönen M; Holopainen M; Turunen SP; Sihto H; Burghardt I; Joensuu H; Tynninen O; Jääskeläinen J; Weller M; Lehti K; Käkelä R; Laakkonen P
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31068339
[TBL] [Abstract][Full Text] [Related]
5. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer.
Byeon HK; Ku M; Yang J
Exp Mol Med; 2019 Jan; 51(1):1-14. PubMed ID: 30700700
[TBL] [Abstract][Full Text] [Related]
6. Filopodome Mapping Identifies p130Cas as a Mechanosensitive Regulator of Filopodia Stability.
Jacquemet G; Stubb A; Saup R; Miihkinen M; Kremneva E; Hamidi H; Ivaska J
Curr Biol; 2019 Jan; 29(2):202-216.e7. PubMed ID: 30639111
[TBL] [Abstract][Full Text] [Related]
7. Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.
Ludovini V; Bianconi F; Siggillino A; Piobbico D; Vannucci J; Metro G; Chiari R; Bellezza G; Puma F; Della Fazia MA; Servillo G; Crinò L
Oncotarget; 2016 May; 7(21):30561-74. PubMed ID: 27081700
[TBL] [Abstract][Full Text] [Related]
8. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
[TBL] [Abstract][Full Text] [Related]
9. Novel target for peptide-based imaging and treatment of brain tumors.
Hyvönen M; Enbäck J; Huhtala T; Lammi J; Sihto H; Weisell J; Joensuu H; Rosenthal-Aizman K; El-Andaloussi S; Langel U; Närvänen A; Bergers G; Laakkonen P
Mol Cancer Ther; 2014 Apr; 13(4):996-1007. PubMed ID: 24493698
[TBL] [Abstract][Full Text] [Related]
10. The Role of EGFR and HER2- Activating Mutations in Maxillary Sinus Cancer.
Ene P; Popescu RC; Voiculescu S; Scaunasu R; Popescu B; Grigore R; Ene R; Cîrstoiu C
Maedica (Bucur); 2012 Jan; 7(1):70-4. PubMed ID: 23118824
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Brand TM; Iida M; Wheeler DL
Cancer Biol Ther; 2011 May; 11(9):777-92. PubMed ID: 21293176
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
[TBL] [Abstract][Full Text] [Related]
13. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Wheeler DL; Dunn EF; Harari PM
Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
[TBL] [Abstract][Full Text] [Related]
14. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance.
Nevo J; Mattila E; Pellinen T; Yamamoto DL; Sara H; Iljin K; Kallioniemi O; Bono P; Heikkilä P; Joensuu H; Wärri A; Ivaska J
Clin Cancer Res; 2009 Nov; 15(21):6570-81. PubMed ID: 19825952
[TBL] [Abstract][Full Text] [Related]
15. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
17. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
18. Molecularly-targeted therapy for the oral cancer stem cells.
Ohnishi Y; Yasui H; Nozaki M; Nakajima M
Jpn Dent Sci Rev; 2018 May; 54(2):88-103. PubMed ID: 29755619
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
